Hormonal Contraceptives Market Report 2025

The hormonal contraceptives market size has grown marginally in recent years. It will grow from $14.16 billion in 2024 to $14.43 billion in 2025 at a compound annual growth rate (CAGR) of 1.9%. The growth in the historic period can be attributed to government initiatives, increase in use of contraceptives, increase in pharmaceutical r&d expenditure, increased healthcare expenditure and growth in the number of healthcare facilities.

The hormonal contraceptives market size is expected to see marginal growth in the next few years. It will grow to $15.53 billion in 2029 at a compound annual growth rate (CAGR) of 1.9%. The growth in the forecast period can be attributed to the increasing awareness on family planning, increasing research and development spending, rise in healthcare expenditure, increasing collaborations between agencies. Major trends in the forecast period include investing in longer lasting vaginal rings, investing in AI solutions to improve medication adherence, launching new innovative products, investing in environmental friendly estrogen profile, investing in improved progestogen only birth control pills, continue to investing in long-term delivery drugs systems.

The heightened awareness surrounding hormonal contraceptives has empowered individuals to make well-informed decisions aligned with their reproductive goals and lifestyles. This increased awareness enables individuals to make choices that better suit their family planning and lifestyle preferences. In September 2023, the World Health Organization (WHO) reported that global contraception prevalence, including any method, reached 65% in 2022, with modern contraceptive methods at 58.7% among married women in a union. Additionally, the global demand for family planning among women increased from 900 million to nearly 1.1 billion in 2021, with a projected global satisfaction rate of 77.5% among women aged 15-49 in 2022. This elevated awareness significantly propels the hormonal contraceptives market.

The escalating rate of unplanned pregnancies is anticipated to drive the growth of the hormonal contraceptive market. Unplanned pregnancies, categorized as unwanted or unplanned, pose a significant global challenge. Hormonal contraceptives offer a reliable and convenient solution to prevent unplanned pregnancies, giving individuals and couples greater control over family planning. According to the United Nations Population Fund in March 2022, there were 121 million unintended pregnancies globally each year, with Afghanistan projected to experience 4.8 million unintended pregnancies in 2025. Thus, the increasing rate of unplanned pregnancies is expected to fuel the growth of the hormonal contraceptives market.

Companies are innovating by introducing chewable, low-dose oral contraceptives to reduce side effects and enhance daily regimen adherence. The availability of chewable contraceptives as an over-the-counter product aims to improve patient compliance and minimize side effects. Leading companies, such as Lupin Pharmaceuticals, Walter Chilcott, and Watson Pharmaceuticals, are actively participating in this initiative.

Major companies in the hormonal contraceptives market are developing advanced products, such as nonprescription daily oral contraceptives, to improve accessibility and convenience for users. A nonprescription daily oral contraceptive is a type of birth control pill that can be purchased without a prescription from a healthcare provider. For example, in July 2023, Perrigo Company PLC, a US-based manufacturer of private label over-the-counter pharmaceuticals, received approval from the Food and Drug Administration (FDA), a US federal agency responsible for protecting public health, for Opill. Opill is the first nonprescription daily oral contraceptive available to consumers without a prescription. The launch of Opill represents a significant advancement in reproductive health, allowing individuals to access effective birth control without the obstacles of needing a prescription or a healthcare appointment.

Major companies operating in the hormonal contraceptives market include Bayer AG, Merck & Co. Inc, Viatris, Gedeon Richter, AbbVie, Pfizer, Teva Pharmaceuticals, Mayne Pharma Group Limited, Lupin Limited, HLL Lifecare Limited, Amneal Pharmaceuticals, DKT International, Piramal Pharma Limited, Allergan, Afaxys Inc., Agile Therapeutic, Cipla Limited, Glenmark Pharmaceuticals, Novartis AG, Sun Pharmaceutical Industries Ltd., Apothecus Pharmaceutical Corporation, Famy care, Mylan Laboratories.

North America was the largest region in the hormonal contraceptives market share in 2024. Middle East is expected to be the fastest-growing region in the global hormonal contraceptives market analysis during the forecast period. The regions covered in the hormonal contraceptives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hormonal contraceptives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The hormonal contraceptive market includes revenues earned by entities by blocking the release of eggs from the ovaries and thinning the lining of the uterus to prevent pregnancy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

Hormonal contraceptives are a form of birth control that utilizes hormones to prevent pregnancy. There are various types, some of which are reversible, while others are permanent. Certain varieties may also offer protection against sexually transmitted diseases (STDs).

The primary categories of products in oral contraceptive pills include injectable birth control, emergency contraceptive pills, vaginal rings, and others. Oral contraceptive pills, also known as birth control pills, are a class of synthetic steroid hormones that inhibit the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior lobe of the pituitary gland in the female body. These pills come in different hormonal compositions, including progestin-only and combined hormones, and find applications in hospitals, homecare settings, gynecology centers, clinics, and ambulatory surgical centers. Distribution channels for these products include drug stores, gynecology or fertility clinics, e-commerce, and others.

The hormonal contraceptives market research report is one of a series of new reports that provides hormonal contraceptives market statistics, including hormonal contraceptives industry global market size, regional shares, competitors with a hormonal contraceptives market share, detailed hormonal contraceptives market segments, market trends and opportunities, and any further data you may need to thrive in the hormonal contraceptives industry. This hormonal contraceptive market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.